Reduction in the duration of neutropenia and the impact of febrile neutropenia in patients with malignant tumors treated with cytotoxic chemotherapy (excluding chronic mieloid leukemia and myelodysplastic syndromes).
- Bennett CL, Djulbegovic B, Norris LB, et al: Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 368:11311139, 2013
- Cooper KL, Madan J, Whyte S, et al: Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer 11:404, 2011
- Weycker D, Li X, Edelsberg J, et al: Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 10:47-54, 2015
- Herbst C, Naumann F, Kruse EB, et al: Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 1:CD007107, 2009